Funding: InSightec closes $30.9 million Series C round
InSightec completes $30.9 million Series C financing round, led by GE Healthcare and other investors. Lands CE Marked approval for its ExAblate Neuro in the treatment of Parkinson's disease.
InSightec picked off $30.9 million in a Series C financing round, led by a $27.6 million investment from GE Healthcare and $3.3 million by other investors, the company said.
In addition, the Israeli-based ultrasound maker also named VP & general manager of the MRI business James Davis as new CEO and Tom Gentile as chairman of board. Gentile most recently was
president & CEO of GE Healthcare.